Free provider profile
FAISAL CHAUDHARY, M.D.
Need more providers like FAISAL CHAUDHARY?
See the count and top 3 free, ranked by Medicare billing. Full list $29, included with membership.
Rep intel
What FAISAL CHAUDHARY prescribes and who else does
Top Medicare Part D drugs by claims (public CMS data):
- Xeljanz Xr
- Enbrel Sureclick
- Rinvoq
- Humira(Cf) Pen
- Humira Pen
See all internal medicine physicians in NY who bill Medicare →
Your next referral list starts here
Provider + market indicator
A combined screening indicator—not a provider fraud-risk score. Local plan ratings describe the surrounding market, not this provider’s quality, plan membership or wrongdoing.
Comparing current CMS billing with peers and checking OIG and plan ratings… A new peer comparison can take about a minute.
Practice contact card
Practice phone
518-584-4953
Fax
518-584-4088
Practice address
6 CARE LANE, SARATOGA SPRINGS, NY, 12866
- Registry updated
- 2021-04-22
- NPI issued
- 2008-06-21
- RepVector retrieved
- 11/20/2026
A recent retrieval can still contain an old address if the provider has not updated their registry record. Website email checks show their own date under Find email.
Registry record
Source: CMS NPPES registry.
6 CARE LANE, SARATOGA SPRINGS, NY, 12866
518-584-4953
Single practice location
Enumerated 2008-06-21
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 2 taxonomies listed — broader service mix.
- — Record last updated 5 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
6,521
Medicare patients
804
Part D drug cost
$6,663,045
Brand-name share
15%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Enbrel Sureclick (Etanercept) | 182 | $1,606,363 |
| Xeljanz Xr (Tofacitinib Citrate) | 194 | $1,186,383 |
| Humira Pen (Adalimumab) | 57 | $601,540 |
| Humira(Cf) Pen (Adalimumab) | 67 | $569,292 |
| Rinvoq (Upadacitinib) | 71 | $463,328 |
| Skyrizi Pen (Risankizumab-Rzaa) | 19 | $412,126 |
| Otezla (Apremilast) | 49 | $323,842 |
| Enbrel (Etanercept) | 27 | $249,968 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Latest Medicare Part B billing
CMS Physician and Other Practitioners, by Provider and Service. New published billing years are detected daily, using the same release as the Billing analyst and risk maps.
Loading the latest published CMS billing file…
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
Checking Open Payments…
Industry payments across NY — which companies pay providers there.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.
